Dentie you’re right and your thorough analysis shows Management...

Dentie you’re right and your thorough analysis shows Management is still OVERTRADING and heading CDY to insolvency despite the CR being a stay of execution.

They can’t manage basic business principles like sound debtor collection, cost control and budgeting. Do they have a CFO or instead a part time booker?

The defence absent of reason posted today by oogerb, (question whether a disciple of the CEO) was, with due respect, wayward in attempting to white ant Dentie’s analysis with irrelevant distraction by saying: “You can’t apply the same valuation methodologies to a biotech as you would a corner store.”

Dentie neither mentioned nor applied any valuation methodologies in the analysis; only relevant ratio analysis, sound generic business practices and assessment. The valid overview was a weakened Balance Sheet, mismanagement and evolving serious financial stress. The continual filtered reporting to us focused only on positives is shameful.

A consequence of this >10 years of failure to implement sound stewardship of our company’s core businesses is a collapsing sp and destruction of value of our CDY shareholdings. Were we blindsided and too optimistic in expecting delivery by this management on the real opportunities of those businesses? Perhaps the new directors and the others investing in the CR have been, at least in the short term until the penny drops, also understandably caught up in the great story this stock may have been.

Management no doubt takes comfort by (and fails to adapt or often to do even the common sense thing) by
the curious never ending support by the cohort of CEO disciples here ranging in their unquestioned loyalty on the disciples index from 0.1 to 1.0. You know who they are.

Importantly, the sp has performed better with more shareholder dissent that disciple lack of reason. There may be a lesson in that in the interest of all stakeholders.